Biocon targets launch for generic Wegovy in India by 2027
Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster weight-loss drug Wegovy in India by the end of 2026, with a potential launch through a partner in 2027, CEO Siddharth Mittal said.
The company expects to complete late-stage clinical trials within the next 12 to 18 months.
Biocon is also pursuing regulatory pathways in Canada, where it plans to file for a generic versions of Ozempic this quarter and Wegovy versions later this year. "Subject to approval, we could look at a market launch in late 2026 or early 2027," he said.
"Biocon is actively progressing with filings for semaglutide in Canada as well as many other emerging markets," Mittal told Reuters.
The push comes after Danish drugmaker Novo Nordisk and U.S.-based rival Eli Lilly saw skyrocketing demand for their obesity drugs Wegovy and Zepbound.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.